



## BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference

June 13, 2019

TEL AVIV, Israel, June 13, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at the JMP Securities 2019 Life Sciences Conference on Wednesday, June 19, 2019 at 2:00 p.m. (EDT). The conference will be held at the St. Regis New York, NY.

A live webcast of the presentation will be available on [BioLineRx's website](#). A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

### About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is being investigated in a Phase 1/2a study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD, on the basis of which the Company is conducting a Phase 2a study in pancreatic cancer using the combination of BL-8040 and KEYTRUDA® (pembrolizumab), and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.

For additional information on BioLineRx, please visit the Company's website at [www.bioplinrx.com](http://www.bioplinrx.com), where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on [Facebook](#), [Twitter](#), and [LinkedIn](#).

### Contact:

Tim McCarthy  
LifeSci Advisors, LLC  
+1-212-915-2564  
[tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)

or

Tsipi Haitovsky  
Public Relations  
+972-52-598-9892  
[tsipihai5@gmail.com](mailto:tsipihai5@gmail.com)

 View original content: <http://www.prnewswire.com/news-releases/biolinerx-to-present-at-the-jmp-securities-2019-life-sciences-conference-300867039.html>

SOURCE BioLineRx Ltd.